The trends are clear: patients and institutions across the nation are concerned about skyrocketing drug prices. This post offers some information about drug pricing, explores the notion of market intervention, and proposes a series of responses to high...
Filed under: Public Health, Featured, Payment Policy, Costs and Spending, Medicaid and CHIP, Drugs and Medical Technology, FDA, hepatitis C, CMS, Big Pharma, Gilead Sciences, Pricewaterhouse Coopers